Company intelligence / Profile preview

VSL Pharmaceuticals, Inc.

Ownership: Private
Development stage: Commercial

Overview

VSL Pharmaceuticals produces high-potency multi-strain probiotic products that have shown efficacy in clinical trials for treating gastrointestinal disorders including ulcerative colitis, pouchitis, and IBS. Their products have also demonstrated benefits for liver cirrhosis, hepatic encephalopathy, and non-alcoholic fatty liver disease.

Therapeutic areas: Gastroenterology
Modalities: Probiotics
Industry: Biotech

Drug pipeline

2 assets

VSL#3

Commercial

Indications: Irritable bowel syndrome, Ulcerative colitis, Pouchitis

1 more asset in the full pipeline.

Request access →

Partnerships

Ferring Pharmaceuticals (marketing rights in Europe and Canada)Leadiant Biosciences, Inc.Alfasigma USA, Inc.

Beyond the preview

Go deeper on VSL Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSL Pharmaceuticals, Inc..

Explore the full profile